Overview
RNXT market data
Price History
RNXT price chart · 1M
- O
- 1.33
- H
- 1.55
- L
- 1.29
- C
- 1.45
- Vol
- 6,927.00
- Source
- US equities market feed
- Observed
- Aug 25, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.33
- Previous Close
- $1.25
- Day High
- $1.55
- Day Low
- $1.29
- 52 Week High
- $1.55
- 52 Week Low
- $0.77
- 7 Day Return
- +23.93%
- 30 Day Return
- +47.96%
- 90 Day Return
- +57.63%
- 1 Year Return
- +74.22%
- Daily Notional Volume
- $10K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.32 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.79 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -824.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.70 – $1.51 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $56.8M · P/B 5.68 · P/S 38.12.
Company News
RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.Benzinga · Aug 25, 2026, 5:26 PM
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Aug 25, 2026, 5:06 PM
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic ExposureBenzinga · Aug 25, 2026, 12:36 PM
8-K filing — RenovoRx, Inc. (RNXT)SEC EDGAR · Aug 20, 2026, 8:05 PM
RenovoRx Says USPTO Issues Notice Of Allowance For Patent Application Titled Methods And Apparatuses For Delivery Of Therapeutic Materials For The Treatment Of CancerBenzinga · Aug 20, 2026, 12:34 PM
RenovoRx Raises FY2026 Sales Guidance from $3.000M-$4.000M to $3.750M-$4.250M vs $3.203M EstBenzinga · Aug 12, 2026, 8:15 PM
RenovoRx Q2 Adj. EPS $(0.05) Beats $(0.07) Estimate, Sales $909.000K Beat $716.500K EstimateBenzinga · Aug 12, 2026, 8:09 PM
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027Benzinga · Aug 11, 2026, 12:01 PM
EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027Benzinga · Aug 11, 2026, 12:00 PM
RenovoRx shares are trading higher after the company announced the first commercial clinical use of RenovoCath for drug-delivery in the treatment of a patient with sarcoma at the CARTI Cancer Center Little Rock.Benzinga · Aug 6, 2026, 5:09 PM